Safety and immunogenicity of CoronaVac in healthy adults: A prospective observational multicenter real-world study in Henan Province, China-Reference-Cited by-同舟云学术

Safety and immunogenicity of CoronaVac in healthy adults: A prospective observational multicenter real-world study in Henan Province, China

Published:2024-02-07 Issue:1 Volume:15 Page:
ISSN:2150-5594
Container-title:Virulence
language:en
Short-container-title:Virulence

Author:

Rao Benchen¹²³,Wang Ling⁴,Yang Mengzhao¹²³,Luo Hong⁵,Sun Junyi¹²³,Liu Shanshuo¹²³,Wang Haiyu¹²³,Wang Xuemei¹²³,Li Lei¹²³,Yuan Chengyu⁵,Yu Zujiang¹²,Ren Zhigang¹²³^ORCID

Affiliation:

1. Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

2. Gene Hospital of Henan Province/Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

3. Jinan Microecological Biomedicine Shandong Laboratory, Jinan, China

4. Department of Laboratory Medicine, Henan Provincial Chest Hospital, Zhengzhou, China

5. Department of Laboratory Medicine, Guangshan County People’s Hospital, Xinyang, Henan, China

Funder

National Key Research and Development Program of China

Henan Province Epidemic Prevention and Control Emergency Scientific Research Project

Central Plains Talents Program Central Plains Youth Top Talent Funding

Young and middle-aged academic leaders of Henan Provincial Health Commission

Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University

Research Project of Jinan Microecological Biomedicine Shandong Laboratory

Independent and Innovation Project for Graduate Students of Academy of Medical Science of Zhengzhou University

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21505594.2024.2310450

Reference25 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

3. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

4. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

5. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine